Wireless Local Area Network (WLAN) offloading is an important approach to address the data traffic challenge faced by Long Term Evolution (LTE) network. Legacy offloading solutions based on the core network suffer fro...Wireless Local Area Network (WLAN) offloading is an important approach to address the data traffic challenge faced by Long Term Evolution (LTE) network. Legacy offloading solutions based on the core network suffer from the limitations of load unbalance and user experience degradation. To solve this problem, 3GPP has recently proposed a radio access network (RAN) assisted WLAN offloading scheme. In this article, we thoroughly analyze the performance of this new scheme, with emphasis on the RAN auxiliary parameters and control rules defined in it. Furthermore, two kinds of offloading algorithms based on this scheme are proposed and compared with the traditional solutions by simulation. Results show that the RAN-assisted offloading scheme can increase average user throughput and leverage resources available in both LTE and WLAN systems.展开更多
Glucagon-like peptide-1(GLP-1)and glucose-dependent insulinotropic polypeptide(GIP)receptor agonists are increasingly used in the management of type 2 diabetes mellitus and obesity due to their ability to stimulate in...Glucagon-like peptide-1(GLP-1)and glucose-dependent insulinotropic polypeptide(GIP)receptor agonists are increasingly used in the management of type 2 diabetes mellitus and obesity due to their ability to stimulate insulin secretion,delay gastric emptying,and suppress appetite.The combination of GLP-1 and GIP agonists improves glycemic control and promotes weight loss.However,the introduction of these novel therapies has raised safety concerns,including the risk of cholestatic hepatitis.We report a case of a patient with obesity who was prescribed a GLP-1/GIP dual-receptor agonist as part of his treatment regimen.Importantly,both before the initiation of this therapy and during the course of treatment,the patient was not taking any other medications.Shortly after receiving four doses of the therapy,the patient developed symptoms of severe cholestatic hepatitis,including jaundice and elevated liver enzyme levels.During hospitalization,no alternative causes for the condition were identified,and a liver biopsy confirmed the diagnosis of druginduced cholestatic hepatitis.This is the first recorded case of cholestatic hepatitis induced by a GLP-1/GIP dual agonist,and it aimed to raise global awareness of this potential side effect.展开更多
文摘Wireless Local Area Network (WLAN) offloading is an important approach to address the data traffic challenge faced by Long Term Evolution (LTE) network. Legacy offloading solutions based on the core network suffer from the limitations of load unbalance and user experience degradation. To solve this problem, 3GPP has recently proposed a radio access network (RAN) assisted WLAN offloading scheme. In this article, we thoroughly analyze the performance of this new scheme, with emphasis on the RAN auxiliary parameters and control rules defined in it. Furthermore, two kinds of offloading algorithms based on this scheme are proposed and compared with the traditional solutions by simulation. Results show that the RAN-assisted offloading scheme can increase average user throughput and leverage resources available in both LTE and WLAN systems.
文摘Glucagon-like peptide-1(GLP-1)and glucose-dependent insulinotropic polypeptide(GIP)receptor agonists are increasingly used in the management of type 2 diabetes mellitus and obesity due to their ability to stimulate insulin secretion,delay gastric emptying,and suppress appetite.The combination of GLP-1 and GIP agonists improves glycemic control and promotes weight loss.However,the introduction of these novel therapies has raised safety concerns,including the risk of cholestatic hepatitis.We report a case of a patient with obesity who was prescribed a GLP-1/GIP dual-receptor agonist as part of his treatment regimen.Importantly,both before the initiation of this therapy and during the course of treatment,the patient was not taking any other medications.Shortly after receiving four doses of the therapy,the patient developed symptoms of severe cholestatic hepatitis,including jaundice and elevated liver enzyme levels.During hospitalization,no alternative causes for the condition were identified,and a liver biopsy confirmed the diagnosis of druginduced cholestatic hepatitis.This is the first recorded case of cholestatic hepatitis induced by a GLP-1/GIP dual agonist,and it aimed to raise global awareness of this potential side effect.
